Cyclooxygenase-2 (COX-2), aromatase and breast cancer: A possible role for COX-2 inhibitors in breast cancer chemoprevention

Annals of Oncology

Volumn 13, Issue 5, 2002, Pages 669-678

  Davies, G ^a   Martin, L A ^a   Sacks, N ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase; Breast cancer; Cyclooxygenase 2; Oestrogens; Prevention; Prostaglandins

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; ACETYLSALICYLIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 1; CYTOKINE; GROWTH FACTOR; PHORBOL ESTER; PROSTAGLANDIN; PROSTAGLANDIN E2;

ANIMAL; BREAST TUMOR; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; LICENCE; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AROMATASE; BREAST NEOPLASMS; CHEMOPREVENTION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; ANIMAL; HUMAN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE;

EID: 0035985272     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf125     Document Type: Review

References (100)

1. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol
2. Aspirin use and reduced risk of fatal colon cancer
3. Reduced risk of large-bowel adenomas among aspirin users
4. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
5. Aspirin use, cancer, and polyps of the large bowel
6. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
7. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
8. Increased cyclo-oxygenase-2 levels in carcinogen-induced rat colonic tumors
9. Elevated cyclooxygenase-2 levels in Min mouse adenomas
10. Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis
11. Up-regulation of cyclo-oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
12. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
13. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
14. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
15. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
16. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
17. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
18. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
19. Prospective study of regular aspirin use and the risk of breast cancer
20. Nonsteroidal antiinflammatory drugs and breast cancer
21. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
22. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
23. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
24. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
25. Aspirin and the potential role of prostaglandins in colon cancer
26. Prostaglandin synthase 2
27. Cyclooxygenase-2 induction: Molecular mechanism and pathophysiologic roles
28. PPARΔ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
29. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARΔ
30. Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells
31. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways
32. Tumor necrosis factor-α-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IκB kinase 1/2 in human alveolar epithelial cells
33. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines
34. Strong association between c-myb and oestrogen-receptor expression in human breast cancer
35. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa
36. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB
37. Cyclooxygenase-2 gene expression in human breast cancer
38. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
39. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps
40. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
41. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
42. Suppression of intestinal polyposis in ApcΔ 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2)
43. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
44. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
45. Increased expression of cyclooxygenase-2 in HER-2-overexpressing human breast cancer cells
46. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers
47. The production of prostanoids in human cancers, and their implications for tumor progression
48. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells
49. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators
50. Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas
51. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas
52. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas
53. Modulation of rat mammary carcinogenesis by indomethacin
54. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor
55. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats
56. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
57. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
58. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors
59. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
60. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
61. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
62. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
63. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
64. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small-cell lung carcinoma
65. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: Possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases
66. NSAIDs inhibit αVβ3 integrinmediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis
67. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
68. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
69. Role of BAX in the apoptotic response to anticancer agents
70. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
71. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey
72. A prospective study of endogenous hormones and breast cancer
73. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
74. Serum sex hormone levels after menopause and subsequent breast cancer
75. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk
76. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione
77. Oestradiol synthesis from C19 steroids by human breast cancers
78. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation
79. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders
80. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers
81. Aromatase activity in adipose tissue from breast quadrants: A link with tumour site
82. The importance of local synthesis of estrogen within the breast
83. Link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
84. The control and biological importance of intratumoural aromatase in breast cancer
85. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction
86. A unique aromatase (P-450arom) mRNA formed by alternative use of tissue-specific exons I in human skin fibroblasts
87. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue
88. Characterization of the sequences of the human CYP19(aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes
89. Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19) gene in the ovary
90. A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene
91. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene
92. Interleukin-1 and interleukin-6 in breast cyst fluid: Their role in regulating aromatase activity in breast cancer cells
93. The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2
94. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
95. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
96. Risk of cardiovascular events associated with selective COX-2 inhibitors
97. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
98. Aspirin use and chronic diseases: A cohort study of the elderly
99. The relationship of nonsteroidal anti-inflammatory drugs use to the risk of breast cancer
100. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage